LAUSR

OBJECTIVE One of the most frequent types of primary liver cancer is hepatocellular carcinoma (HCC). Due to the high incidence of hepatitis B infection, HCC accounts for about 5% of all cancers. HCC is indeed one of the largest leading causes of cancer deaths in the world and the third biggest cause of cancer-related death. The purpose of our research was to see how effective TACE (Trans-Arterial Chemoembolization) therapy was in those who had hepatocellular cancer. MATERIALS AND METHODS The Preferred Reporting Items for Systematic Reviews (PRISMA) statement was used to conduct the systemic review. From their inception through the first week of January 2022, the following electronic databases were thoroughly searched: PubMed, Embase, PsycINFO, and the Cochrane Library, with no language constraints. The search terms were "transarterial chemoembolization" or "chemoembolization" or "TACE" AND "hepatocellular carcinoma" or "hematoma" or "HCC" or "liver cancer" or "liver tumor" AND "sorafenib". The references of the discovered articles were also examined. The search included English papers with adult patients only. RESULTS A total of 1,234 studies were found for screening after searching the literature in multiple databases. 767 papers were removed based on titles and abstracts, but the complete text of the remaining 129 publications was full text and eligible. In total, 13 studies were included in this research. The study's screening flowchart was depicted using the PRISMA technique. The majority of the findings was of a small magnitude. Even with chronic liver disease and huge tumor groupings, they agreed on the safety and efficacy of such multiple closures prior to plan resection (50 mm). Even after curative resection, the prognosis for these patients remains poor because of portal vein thrombosis, high frequency of liver failure, and microscopic tumor thrombosis. CONCLUSIONS TACE is a low-cost palliative treatment for HCC. The initial tumor size is an independent predictor of survival.